Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings
MedCity News
SEPTEMBER 18, 2022
The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.
67 
Let's personalize your content